DIAGENS-B's stock price surged 5.41% during intraday trading on Wednesday, extending its recent positive momentum in the market.

The significant upward movement appears driven by a combination of strong financial performance and promising regulatory developments. The company recently reported outstanding first-quarter results, with net profit reaching 5.8 billion yuan, representing a 12.3% year-over-year increase. Additionally, gross margin improved to 38.7%, up 2.1 percentage points quarter-over-quarter, significantly exceeding market expectations.

Beyond the financial strength, the company's AI AutoVision product has been recognized by China's National Medical Products Administration as a Class III innovative medical device. Following communication with regulatory authorities in December, no objections to the product's registration approval have been raised, with only procedural and administrative matters remaining. If ultimately approved, AI AutoVision would become the first intelligent chromosome karyotype-assisted diagnostic software to receive market authorization in China.